An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Better Therapeutics (NASDAQ: BTTX) has announced an educational symposium titled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.” This event addresses the significant spending on cardiometabolic diseases, emphasizing a shift towards prescription digital therapeutics (PDTs) that utilize cognitive behavioral therapy. The symposium, moderated by a Harvard Medical School cardiologist, focuses on delivering evidence-based solutions to improve patient outcomes and reduce healthcare costs. Better Therapeutics aims to transform treatment approaches with FDA-regulated, software-based solutions.
Positive
Launch of an educational symposium on PDTs for cardiometabolic diseases.
Collaboration with medical experts from reputable institutions.
Potential for PDTs to lower healthcare costs while improving patient health.
Negative
None.
Medical experts discuss the potential use of prescription digital therapeutics (PDTs) delivering cognitive behavior therapy to address behavioral root causes of disease
The role of data generated through randomized, controlled trials and real-world evidence studies on payer coverage and reimbursement is examined
SAN FRANCISCO--(BUSINESS WIRE)--
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in collaboration with MedEd On The Go, today announced the availability of an on-demand, educational symposium entitled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.”
The on-demand educational symposium is moderated by Christopher Cannon, MD, professor at Harvard Medical School and cardiologist at Brigham and Women’s Hospital, and it includes panelists Marc Bonaca, MD, executive director of Colorado Prevention Center Clinical Research and associate professor at University of Colorado; Maria Lopes, MD, chief medical officer at AMC Health; and Benjamin Scirica, MD, associate professor at Harvard Medical School and cardiologist at Brigham and Women’s Hospital.
“Nearly half a trillion dollars are spent each year dealing with the symptoms of type 2 diabetes, heart disease and other cardiometabolic conditions, while little is done to address the behaviors that are root causes,” said Kevin Appelbaum, CEO of Better Therapeutics. “PDTs that use software instead of drugs to deliver a new kind of cognitive behavior therapy shows promise as a treatment alternative that can address the root causes of disease, improving patient health while reducing healthcare costs and the ongoing need for medications.”
The symposium highlights the scope of the problem in type 2 diabetes, application of cognitive behavioral therapy in the form of a PDT, the evidence standards for payer evaluation and coverage, and how Better Therapeutics’ pivotal trial and real-world evidence program will meet providers and payer evidence needs. The educational symposium can be accessed in its entirety via: www.mededonthego.com/refer/name/BetterTxPR852
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
What is the focus of the Better Therapeutics symposium?
The Better Therapeutics symposium focuses on prescription digital therapeutics (PDTs) and their application in treating cardiometabolic diseases using cognitive behavioral therapy.
How does Better Therapeutics plan to address cardiometabolic diseases?
Better Therapeutics aims to address cardiometabolic diseases through software-based cognitive behavioral therapy, which targets the root behavioral causes of conditions like type 2 diabetes and heart disease.
What are the benefits of prescription digital therapeutics according to Better Therapeutics?
According to Better Therapeutics, prescription digital therapeutics may improve patient health outcomes and reduce healthcare costs compared to traditional medication approaches.
Who moderated the symposium on Better Therapeutics' new treatments?
The symposium was moderated by Christopher Cannon, MD, a professor at Harvard Medical School.
